Concord Biotech IPO Details
- Open Date 04-Aug-23
- Close Date 08-Aug-23
- Lot Size 20
- IPO Size ₹ 1,551 Cr
- IPO Price Range ₹ 705 to ₹ 741
- Min Investment ₹ 14100
- Listing Exchange BSE, NSE
- Basis of Allotment 11-Aug-23
- Refunds 14-Aug-23
- Credit to Demat Account 17-Aug-23
- Listing Date 18-Aug-23
Concord Biotech IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 04-Aug-23 | 0.01 | 1.01 | 0.73 | 0.59 |
| 07-Aug-23 | 1.61 | 5.22 | 2.26 | 2.72 |
| 08-Aug-23 | 67.67 | 16.99 | 3.78 | 24.86 |
Concord Biotech IPO Synopsis
Concord Biotech Limited IPO is all set to open from 4th August to 8th August 2023. Concord Biotech is an R&D-led biopharma company based out of India. The IPO includes an Offer-for-Sale (OFS) of 20,925,652 equity shares ₹1551 crore. The share allotment date is 11th August, and the IPO will be listed on 18th August on the stock exchanges. The price band is ₹705 to ₹741, and the IPO size is 20 shares.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book-running lead managers for this IPO, while Link Intime India Private Limited is the registrar.
Objectives of Concord Biotech IPO
Concord Biotech plans to utilize the raised capital from IPO to:
● Benefit from stock listing on exchanges
● To undertake OFS for the selling shareholders
Concord Biotech IPO Video:
About Concord Biotech
Founded in 1984, Concord Biotech Limited, headquartered in Ahmedabad, is a research and development-driven biopharmaceutical company. It is renowned globally for its expertise in developing and manufacturing Active Pharmaceutical Ingredients (API) using fermentation and semi-synthetic processes, as well as finished formulations. The company has a vast global presence, with over 200 customers in more than 70 countries. It also has a well-established distribution network in key markets such as the USA, Europe, Japan, Latin America, Africa, Asia, and a significant market share in India.
Concord Biotech has 3 manufacturing facilities located in Gujarat, India. Additionally, it has 2 R&D units that have received DSIR (Department of Scientific and Industrial Research) approval, comprising 163 members as of March 31, 2022. The company specializes in producing six fermentation-based immunosuppressant APIs, which include tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. As of March 31, 2022, the company offered a total of 22 API products.
Peer Comparison
● Suven Pharmaceuticals Limited
● Divi’s Laboratories Limited
● Shilpa Medicare Limited
● Laurus Labs Limited
For More Information:
Concord Biotech IPO Allotment Status
Webstory on Concord Biotech IPO
Concord Biotech IPO GMP
Concord Biotech Financial Status
Profit and Loss
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue | 853.16 | 712.93 | 616.94 |
| EBITDA | 568.42 | 495.19 | 317.58 |
| PAT | 240.08 | 174.92 | 234.88 |
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Total Assets | 1513.98 | 1312.79 | 1182.54 |
| Share Capital | - | - | - |
| Total Borrowings | 223.98 | 209.57 | 183.17 |
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Net cash generated from / (used in) operating activities | 246.00 | 207.47 | 166.81 |
| Net cash from / (used in) investing activities | -157.94 | -111.78 | -195.20 |
| Net cash flow from / (used in) financing activities | -85.22 | -100.16 | 31.12 |
| Net increase (decrease) in cash and cash equivalents | 2.83 | -4.47 | 2.73 |
Concord Biotech IPO Key Points
-
Strengths
1. Concord Biotech held a market share exceeding 20% by volume for fermentation-based Active APIs, including mupirocin in 2022.
2. The company has a strong presence throughout the complex fermentation value chain.
3. The company has a diversified global customer base and maintains long-standing relationships with key clients
4. It has strong financial performance with rapid growth, consistent profitability, healthy cash flows, and satisfying returns to shareholders.
5. The company is dedicated to developing specialized and intricate fermentation-based products having high growth potential.
-
Risks
1. The company is dependent on a few customers for a major revenue share.
2. It is subject to extensive government regulations.
3. There is a risk of volatile foreign exchange rates.
4. The working capital needs are on the higher side.
5. The company enjoys certain incentive schemes by the government. Any change or discontinuation in availing of such schemes can impact the business operations and profitability.
6. Any national or global health emergency or restriction can impact the business.
7. Operates in a highly competitive industry.
How to apply for IPO?
-
Login to your 5paisa account and select the issue in the
current IPO section -
Enter the number of lots and price at which you wish to
apply for -
Enter your UPI ID and click on submit. With this, your
bid will be placed with the exchange -
You will receive a mandate notification to block funds in
your UPI app -
Approve the mandate request on your UPI and funds
will be blocked
Open account in 5 minutes
Be a part of the 5paisa community now with 10 million mobile app users
Concord Biotech IPO FAQs
What is the minimum lot size and investment required for the Concord Biotech IPO?
The minimum lot size of Concord Biotech IPO is 20 shares, and the investment required is ₹14,100.
What is the price band of Concord Biotech IPO?
The price band of Concord Biotech IPO is ₹705 to ₹741.
When does the Concord Biotech IPO opens and closes?
Concord Biotech IPO opens on 4th August and closes on 8th August 2023.
What is the size of the Concord Biotech IPO?
The size of Concord Biotech IPO is ₹1551 crore.
What is the allotment date of the Concord Biotech IPO?
The share allotment date of the Concord Biotech IPO is 11th of August.
What is the Concord Biotech IPO listing date?
The Concord Biotech IPO will be listed on the 18th of August.
Who are the book runners for the Concord Biotech IPO?
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, and Jefferies India Private Limited are the book-running lead managers for Concord Biotech IPO.
What is the objective of Concord Biotech IPO?
Concord Biotech plans to utilize the raised capital from IPO to:
1. Benefit from stock listing on exchanges
2. To undertake OFS for the selling shareholders
How to apply for the Concord Biotech IPO?
To apply for Concord Biotech IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Concord Biotech Limited IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
● You will receive a mandate notification to block funds in your UPI app.
Contact Details of Concord Biotech IPO
Contact Information
Concord Biotech Limited
1482-86,
Trasad Road Dholka,
Ahmedabad – 382225
Phone: 079-6813 8700
Email: complianceofficer@concordbiotech.com
Website: http://www.concordbiotech.com/
Concord Biotech IPO Register
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: concordbiotech.ipo@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Concord Biotech IPO Lead Manager
Kotak Mahindra Capital Company Limited
Citigroup Global Markets India Private Limited
Jefferies India Private Limited